|
Immune response triggered by a novel molecular crosstalk of major hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways. |
|
|
Research Funding - Proacta |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Proacta (Inst) |
|
|
Employment - Biocartis; Novartis; Roche/Genentech |
Stock and Other Ownership Interests - Biocartis |
Consulting or Advisory Role - Onyx |
Patents, Royalties, Other Intellectual Property - Co inventor for several patents, no royalties. |
|
|
Honoraria - Bayer; Celgene; Merck Serono; Roche |
Consulting or Advisory Role - Bayer; Celgene; Merck Serono; Roche |
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche |
|
|
No Relationships to Disclose |